333 related articles for article (PubMed ID: 18050263)
1. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
2. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.
Pincus T; Yazici Y; van Vollenhoven R
J Rheumatol; 2006 Dec; 33(12):2372-5. PubMed ID: 17143975
[No Abstract] [Full Text] [Related]
3. Anti-tumour necrosis factor therapy in the West Midlands.
Bartram D; Sheeran T; Price T; Mulherin D
Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
[No Abstract] [Full Text] [Related]
4. [TNF antagonists in therapy of rheumatoid arthritis].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
[No Abstract] [Full Text] [Related]
5. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
6. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
7. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
Erkan D; Yazici Y; Harrison MJ; Paget SA
Arthritis Rheum; 2002 Jun; 47(3):285-90. PubMed ID: 12115159
[TBL] [Abstract][Full Text] [Related]
8. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients.
Duclos M; Gossec L; Ruyssen-Witrand A; Salliot C; Luc M; Guignard S; Dougados M
J Rheumatol; 2006 Dec; 33(12):2433-8. PubMed ID: 17014004
[TBL] [Abstract][Full Text] [Related]
9. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
Tsutani K; Igarashi A
Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
[No Abstract] [Full Text] [Related]
10. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
11. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
12. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
13. The role of tumor necrosis factor inhibitors in patients with RA.
Trethewey P
JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
[No Abstract] [Full Text] [Related]
14. Etanercept or infliximab: the patient's considerations.
Sherrick RC
Arch Intern Med; 2006 Jul; 166(13):1418; author reply 1418. PubMed ID: 16832010
[No Abstract] [Full Text] [Related]
15. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
Kaplan MJ
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
[No Abstract] [Full Text] [Related]
16. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
Vander Cruyssen B; Ribbens C; Boonen A; Mielants H; de Vlam K; Lenaerts J; Steinfeld S; Van den Bosch F; Dewulf L; Vastesaeger N
Ann Rheum Dis; 2007 Aug; 66(8):1072-7. PubMed ID: 17261531
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
[No Abstract] [Full Text] [Related]
18. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Scott DL; Kingsley GH
N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
[No Abstract] [Full Text] [Related]
19. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
Dayer JM; Krane SM
N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
[No Abstract] [Full Text] [Related]
20. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
